TIMELINE

June 30, 2009

I first reported that Bayer Schering (BYERF.PK) could make an offer to acquire SPPI.

August 2, 2009

Reni J. Benjamin, Rodman and Renshaw biotech analyst, told Jonathan Moreland of RealMoney, “[c]ompany's like Bayer or Bristol-Myers (NYSE: BMY) may also look at the company more seriously if they are able to successfully market Zevalin.”

August 4, 2009

I reported SPPI rose 7.16% on speculation that it may be targeted for acquisition.

August 4, 2009

Adam Feuerstein of TheStreet.com (Nasdaq: TSCM) reported he was skeptical about an SPPI buyout.

August 6, 2009

SPPI announced that it acquired the 100% of the rights to RenaZorb® which is currently being studied in trials for hyperphosphatemia in patients with chronic kidney disease.

SPPI is scheduled to report Q2 earnings via webcast on August 13, 2009 at 12:00 PM ET.  Interested investors can access the webcast here.

CONCLUSION

SPPI’s move to acquire all of the rights to RenaZorb® indicates to me that Allergan (NYSE: AGN), who has been working to establish its urological drug division, may now be interested in bidding on SPPI. 

While this is merely speculation on my part, the possibilities certainly appear to be growing, rather than shrinking, along with SPPI’s share price.

Keep your eye on SPPI.

Disclosure: Long SPPI.